Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
You should never feel like you need to self-medicate
Common community options include adding cagrilintide for satiety, adding MOTS-c for mitochondrial support, or adding a GH secretagogue (covered in the Advanced Recomp Stack) for lean mass
No official human dosing standard exists, so doses should be set with a physician
Toft-Nielsen, M
Biological Origin and Expression MOTS-c is translated from a short open reading frame (sORF) within the 12S rRNA region of human mitochondrial DNA, making it one of the few peptides produced directly from mitochondrial DNA
